Featured Research

from universities, journals, and other organizations

Calcium supplementation does not increase coronary heart disease, new study suggests

Date:
April 5, 2014
Source:
International Osteoporosis Foundation
Summary:
Researchers have shown the results of a meta-analysis of randomized controlled trials of calcium supplements. The results do not support the hypothesis that calcium supplementation, with or without vitamin D, increases coronary heart disease or all-cause mortality risk in elderly women.

The results of a study presented today at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases do not support the hypothesis that calcium supplementation, with or without vitamin D, increases coronary heart disease or all-cause mortality risk in elderly women.

The investigators, from centres in Australia, Denmark and the USA, undertook a meta-analysis of randomized controlled trials of calcium supplements with or without vitamin D. They searched for two primary outcomes: coronary heart disease and all-cause mortality verified by clinical review, hospital record or death certificate. The Cochrane Central Register of Controlled Trials, MEDLINE, and EMBASE databases were searched from January 1, 1966 -- May 24, 2013 for potentially eligible studies, reference lists were checked, and trial investigators were contacted where additional data was required. Eligibility criteria included randomized controlled trials of calcium supplementation with or without vitamin D with events with a mean cohort age >50 years. Trial data were combined using a random-effects meta-analysis to calculate relative risk of heart disease events in participants supplemented with calcium.

Of the 661 potentially eligible reports, 18 met the stringent inclusion criteria, contributing information on 63,564 participants with 3,390 coronary heart disease events and 4,157 deaths from any cause. Five trials contributed coronary heart disease events with pooled relative risk (RR) for calcium of 1.02. And 17 trials contributed to all-cause mortality data with pooled RR for calcium of 0.96. The meta-analysis showed that calcium supplementation with or without vitamin D does not increase coronary heart disease or all-cause mortality risk in elderly women.

Abstract reference

OC34 The effects of calcium supplementation on coronary heart disease hospitalisation and death in postmenopausal women: a collaborative meta-analysis of randomised controlled trials. J. R. Lewis, K. L. Ivey, S. Radavelli-Bagatini, L. Rejnmark, J. S. Chen, J. M. Simpson, J. M. Lappe, L. Mosekilde, R. L. Prentice, R. L. Prince. Osteoporos Int. Vol 25, Suppl. 2, 2014


Story Source:

The above story is based on materials provided by International Osteoporosis Foundation. Note: Materials may be edited for content and length.


Cite This Page:

International Osteoporosis Foundation. "Calcium supplementation does not increase coronary heart disease, new study suggests." ScienceDaily. ScienceDaily, 5 April 2014. <www.sciencedaily.com/releases/2014/04/140405105015.htm>.
International Osteoporosis Foundation. (2014, April 5). Calcium supplementation does not increase coronary heart disease, new study suggests. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2014/04/140405105015.htm
International Osteoporosis Foundation. "Calcium supplementation does not increase coronary heart disease, new study suggests." ScienceDaily. www.sciencedaily.com/releases/2014/04/140405105015.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins